BridgeBio (BBIO) investor relations material

Executive summary

• Net product revenue for Q2 2026 surged to $222.4M, up from $71.5M in Q2 2025, driven by Attruby's commercial expansion and regulatory approvals in multiple regions.

• Three late-stage programs (BBP-418, encaleret, infigratinib) advanced to FDA review, with two receiving priority review and launches expected upon approval.

• Closed $1B preferred equity financing post-quarter, boosting cash to $1.7B to support upcoming launches and pipeline expansion.

• Commercial infrastructure and field teams are fully built for all three upcoming launches.

• Attruby demonstrated clinical differentiation, including first evidence of direct kidney protection in ATTR-CM.

Financial highlights

• Q2 2026 total revenues were $243.7M, up from $110.5M in Q2 2025, mainly due to increased Attruby sales and higher royalty revenue.

• Operating expenses rose to $350.8M in Q2 2026, reflecting higher SG&A and R&D investments.

• Net loss for Q2 2026 was $152.2M, improved from $181.9M in Q2 2025.

• Cash, equivalents, and marketable securities were $720.2M at quarter end; $1.7B post-financing.

• Outstanding debt was $2.5B, with deferred royalty obligations of $908.7M.

Outlook and guidance

• Expect continued steady sales growth for Attruby, driven by first-line market expansion and clinical differentiation.

• Three product launches anticipated over the next 12 months, with infrastructure in place.

• Margin expansion expected as Attruby scales, with breakeven profitability targeted by 2027.

• U.S. launches for BBP-418 and encaleret expected upon FDA approval, with PDUFA dates set for November 27, 2026, and May 8, 2027.

• Ongoing investments in R&D and commercialization are projected to drive operating losses for the next several years.